Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Recordati Pharmaceuticals Limited, Origin, Western Road, Bracknell, RG12 1US, United Kingdom
Urispas is indicated for the symptomatic relief of dysuria, urgency, nocturia, vesical supra-pubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethro-cystitis and urethrotrigonitis.
In addition, the preparation is indicated for the relief of vesico-urethral spasms due to catheterisation, cystoscopy or indwelling catheters; prior to cystoscopy or catheterisation; sequelae of surgical intervention of the lower urinary tract.
The recommended adult dosage is one tablet three times a day for as long as required.
The safety and efficacy of Urispas in children aged <12 years have not yet been established.
Oral administration.
The tablets should be taken after a meal in order to prevent nausea.
No risk following overdose has been identified in the post-marketing experience.
3 years.
Do not store above 30°C. Keep blister strips in the outer carton.
PVC/aluminium blister strips in pack sizes of 84, 90, 100 and 250 tablets. Not all pack sizes may be marketed.
Not applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
